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Abstract
Introduction Somatostatin and its analogues inhibit the
growth of various kinds of endocrine and exocrine cells via
the somatostatin receptor (SSTR). Expression of SSTR2A
has been reported in many well-diVerentiated neuroendo-
crine tumors and small numbers of poorly diVerentiated
neuroendocrine carcinomas. SSTR2A-positive neuroendo-
crine tumors may be treatable by SS analogues. Uterine
cervical neuroendocrine carcinoma is generally associated
with poor prognosis.
Materials and methods We examined the expression of
SSTR2A and other neuroendocrine markers [neural cell
adhesion molecule (NCAM), chromogranin A, and synap-
tophysin] by immunohistochemical methods in seven neu-
roendocrine tumors of the uterine cervix: Wve small cell
carcinomas and two large cell neuroendocrine carcinomas.
Results SSTR2A was expressed in one small cell carci-
noma and two neuroendocrine large cell carcinomas. The
cell membrane of cells in these carcinomas showed strong
immunohistochemical reactivity for SSTR2A. SSTR2A-
positive cases are also frequently positive for the expres-
sion of chromogranin A. Treatment with SSTR2A may be
eVective for endocrine tumors. The results indicate the use-
fulness of SSTR2A analogs for the treatment of some uter-
ine neuroendocrine carcinomas.
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Introduction
Well-diVerentiated neuroendocrine tumors, such as carci-
noid tumors and pancreatic endocrine tumors, generally
have a good prognosis. However, poorly diVerentiated
endocrine carcinomas, such as small cell lung cancer, med-
ullary carcinoma, and uterine neuroendocrine carcinomas
have distant metastases in the liver, lung, or bone; neither
chemotherapy nor irradiation therapy is very eVective in
treating them. Neuroendocrine carcinoma of the uterine
cervix has been described as the tumor with the worst prog-
nosis. The mean survival time for patients with this carci-
noma has been reported to be 32.3 months [1].
Somatostatin has a broad spectrum of biological actions;
exerts suppressive eVects on multiple organs, including the
brain, pituitary, gut, exocrine and endocrine pancreas, adre-
nals, thyroid, and kidneys; and appears to be an endogenous
growth inhibitor [2].
The diverse biological eVects of somatostatin are medi-
ated by a family of G protein-coupled receptors [namely,
somatostatin receptors (SSTRs)] that are encoded by Wve
non-allelic genes located on separate chromosomes. The
receptors can be further divided into 5 subtypes. This
review focuses on the molecular pharmacology and func-
tion of these receptors, with particular emphasis on the
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dependent receptor regulation, desensitization responses,
subtype-speciWc eVector coupling, and the signal transduc-
tion pathways responsible for inhibiting cell secretion and
cell growth or induction of apoptosis [3].
Although there have been investigations on the localiza-
tion of SSTR by autoradiography, PCR, and in situ hybrid-
ization (ISH) [4–6], few studies have examined the cellular
localization of the receptor subtype proteins in neuroendo-
crine tumors, especially in metastatic or highly malignant
neuroendocrine tumors [2, 7, 8].
Uterine cervical endocrine carcinoma is rare. Therefore,
there are few reports on the expression of SSTR2A in uter-
ine cervical endocrine carcinoma.
In the present study, we examined the expression of
SSTR2A in uterine cervical neuroendocrine cancers.
Materials and methods
The majority of the specimens investigated were surgically
obtained, and the Wndings were noted in the records of the
Tokai University Hospital. The seven neuroendocrine car-
cinomas of uterine cervix examined included Wve small cell
carcinomas and two large cell neuroendocrine carcinomas.
Two of the former carcinomas were accompanied with
squamous cell carcinoma and adenosquamous cell carci-
noma. In Wve of all the seven cases, there was a distant
metastasis and death from the disease within 2 years after
the operation, except in two current cases (Table 1).
Immunohistochemistry
The tissues were Wxed by immersion in 4% buVered
formaldehyde and embedded in paraYn according to
standard procedures. These tissues were subjected to the
following studies. For immunohistochemical staining, 4-
m sections were deparaYnized and rehydrated. Block-
ing of endogenous peroxidase was done by pretreating
the sections by methanol containing 10% H2O2 for
30 min. The primary antibodies that were used, the proce-
dure for their dilution, and the method of antigen retrieval
from the sections are described in Table 2. The immuno-
histochemical staining for SSTR2A was carried out by
using the Envision/HRP kit (DAKO). The nuclei were
slightly counterstained with hematoxylin. To reveal the
colocalization of immunoreactive SSTR2A and other
neuroendocrine markers (namely, neural cell adhesion
molecule (NCAM), chromogranin A, synaptophysin),
serial sections were cut, and pairs of adjacent sections
were examined (Table 3).
For the positive control specimens of SSTR2A, we used
normal pancreas tissues obtained by autopsy, Wxed by 10%
buVered formalin, and embedded in paraYn.
Evaluation of immunostaining
The results of immunostaining for SSTR2A and other neu-
roendocrine markers were evaluated. When less than 25%
cells were positively stained, the results were classiWed as
+; when 25–50% cells were stained positively, they were
Table 1 ProWle of present cases
DOD death of disease, AWD alive with disease
* Postoperative observation is less than 6 months
Case Age 
(years)
Histopathology pTNM stage Metastatic organs Outcome 
(post-operative months)
1 73 Small + squamous T3aN1 Liver, lung, brain DOD 18M
2 23 Small T2aN1 Liver, bone DOD 11M
3 37 Large cell neuroendocrine T1b2N1 Thyroid, breast, bone, peritoneum DOD 21M
4 55 Large cell neuroendocrine T2aN0 Liver, lung, bone DOD 12M
5 51 Small T2bN0 Liver, adrenal, bone, peritonrum DOD 16M
6 56 Small + adenosquamous T1b1N0 Ascites AWD*
7 50 Small T3bN1MA – AWD*
Table 2 Primary antibodies 
and method of antigen retrieval Code or 
clone
Manufacturer Dilution Antigen retrieval
SSTR2A ss-800 Gramsch 1:500 Boil used by citrate buVer/pH 6.0
NCAM 1B6 Novo castra 1:50 Boil used by citrate buVer/pH 6.0
Chromogranin A Poly Invitrogen 1:1 –
Synaptophysin N1566 DAKO 1:50 1% trypsin123
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stained positively, they were classiWed as +++.
Results
Neuroendocrine carcinomas showed immunohistochemi-
cal expression of NCAM in Wve cases, that of chromogra-
nin A in six cases, and that of synaptophysin in all the
seven cases. In one of the Wve cases of small cell carcinoma
and both the cases of large cell neuroendocrine carcinomas,
positive staining for SSTR2A was observed. SSTR2A-pos-
itive cases also frequently expressed chromogranin A. In a
case where high SSTR2A expression was noted, other
endocrine markers (NCAM, chromogranin A, and synapto-
physin) were also frequently expressed. In the two mixed
tumors comprising of small cell carcinoma and non-neuro-
endocrine carcinoma (squamous cell carcinoma or adeno-
squamous carcinoma), SSTR2A was not expressed in the
non-neuroendocrine components. SSTR2A was detected on
the cell membrane (Figs. 1 and 2).
Discussion
Uterine cervical neuroendocrine tumors are histopathologi-
cally classiWed into four groups: carcinoid tumors, atypical
carcinoid tumors, small-cell carcinomas, and large-cell
neuroendocrine carcinomas [9]. These tumors arise in
reserve cells of the basal epithelial layer, as well as squa-
mous cell carcinoma and adenocarcinoma. Therefore,
mixed tumors of small cell carcinoma and squamous or
Table 3 Result of immuno-
staining Case Endocrine component Non-endocrine components
SSTR2A NCAM CGA SYN SSTR2A NCAM CGA SYN
1 ¡ ¡ + +++ ¡ ¡ ¡ ¡
2 ¡ +++ + +++
3 +++ +++ ++ +++
4 + ¡ +++ +++
5 ¡ ++ ¡ +
6 + +++ ++ + ¡ ¡ ¡ ¡
7 ¡ +++ + ++
Positive rate of expressed neuro-
endocrine tumor cells, ¡ nega-
tive, + less than 25%, ++ 25–
50%, +++ more than 50%
CGA chromogranin A, SYN 
synaptophysin
Fig. 1 Large-cell neuroendo-
crine carcinoma (case 3). Tumor 
cells are frequently positive for 
SSTR2A (b), chromogranin A 
(c) and NCAM (d)123
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cinomas of uterine cervix have been known to detect com-
mon neuroendocrine markers (NCAM, chromogranin A
and synaptophysin) [10, 11].
Neuroendocrine tissues and their tumors have been
found to express SSTR by SSTR autoradiography or ISH of
SSTR mRNA [5, 6, 12]. Reubi et al. comprehensively
investigated the expression of SSTR mRNA in human
tumors by using receptor autography. By using an immuno-
histochemical method, Kimura et al. [2] found that SSTR is
expressed in many well-diVerentiated neuroendocrine car-
cinomas and some poorly diVerentiated neuroendocrine
carcinomas. The tumors were characterized as having
receptors with a high aYnity for the synthetic analogue
octreotide [13]. Janson et al. [6] reported that the expres-
sion of SSTR2 mRNA detected using ISH correlates with
therapeutic outcome in patients with carcinoid tumors
treated with somatostatin analogs.
However, to our knowledge, there have been no immu-
nohistochemical studies of SSTR2A in poorly diVerentiated
neuroendocrine carcinomas of the uterine cervix. As the
numbers of cases studied with the report are rather limited,
therefore is should be mentioned that the current study is a
pilot study and its results should be conWrmed in an
extended study containing larger number of cases. Our
study showed that SSTR2A is the useful neuroendocrine
markers, as well as NCAM, chromogranin A and synapro-
physin, in the uterine cervical neuroendocrine carcinomas
like other neuroendocrine tumors.
A number of somatostatin analogs have been used for
the treatment of acromegaly and endocrine tumors of the
gastroenteropancreatic system [14, 15]. Most of these
tumors and cell lines express SSTR2 [13, 16], and SSTR5
mRNA is also expressed in gastroenteropancreatic tumors
[17]. The activation of a tyrosine phosphatase and the inhi-
bition of calcium mobilization mediated by SSTR2 and
SSTR5, respectively, could be important steps in the nega-
tive mitogenic signal induced by a somatostatin analog
[17]. Janson et al. [6] compared the eYcacy of the SSTR2
mRNA expression and the response to treatment with SS
analog in patients with carcinoid tumors. They concluded
that there was a complete agreement between the presence
of SSTR2 mRNA detected using ISH and a positive thera-
peutic outcome. Recently, they conducted an immunohisto-
chemical study on SSTR2 in the above tumors and obtained
the same results, and concluded that immunohistochemical
methods are applicable in clinical practice [15]. Although
there were no cases of treatment with somatostatin analogs
in the present study, we would like to refer to the possible
utility of somatostatin analogs for treating not only carci-
noid tumors but also malignant neuroendocrine tumors,
including metastatic pheochromocytoma, neuroendocrine
carcinoma, and inWltrating ganglioneuroma, for which there
are no eVective treatments at present. Further practical
investigations of using somatostatin analogs for treating
patients with such tumors should be conducted.
The prognosis of uterine cervical neuroendocrine can-
cers is poor, and no chemotherapy has been known to be
Fig. 2 Small-cell carcinoma 
and squamous cell carcinoma 
(case 6). In the small-cell carci-
noma component, tumor cells 
are positive for SSTR2A (b), 
chromogranin A (c), and NCAM 
(d). In the squamous cell compo-
nent (arrow head), tumor cells 
are negative for SSTR2A and 
NCAM123
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motherapy, including a somatostatin analog (octreotide),
for treating uterine cervical atypical carcinoid tumors [18].
However, the eVect has not been conWrmed. Somatostatin
analogs can be expected eVective for SSTR2A-positive
uterine cervical neuroendocrine neoplasm in future. In
addition, in uterine cervix cancers of mixed histological
type comprising of neuroendocrine and non-neuroendo-
crine components, it seemed that a combination of
somatostatin analogs and conventional chemotherapy was
necessary.
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